Education
About Us
Working with TipRanks
Follow Us
Stereotaxis (STXS)
:STXS
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.05Last Year’s EPS
-0.06Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 03, 2025
|% Change Since: -5.83%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Neutral
Stereotaxis demonstrated strong revenue growth and made significant progress with FDA submissions and strategic acquisitions, which are expected to drive future growth. However, system revenue showed a slight decline, and recurring revenue faced challenges due to external dependencies. The company also reported a higher operating loss and commercial uncertainties in China. Overall, the call presents a balanced picture with potential for future growth tempered by current financial and market challenges.Company Guidance
During the Stereotaxis Fourth Quarter and Full Year 2024 Earnings Conference Call, CEO David Fischel provided detailed guidance on the company's strategic transformation. He outlined four key pillars: making the GenesisX robot widely available, expanding catheter and integration ecosystems in the EP ablation market, developing new interventional devices, and establishing connectivity and AI capabilities in cath labs. Fischel announced significant milestones, including the CE Mark approval for GenesisX in Europe and anticipated regulatory approvals for the MAGIC ablation catheter and MAGIC Sweep high-density mapping catheter in the US and Europe by Q3 2025. The company expects MAGIC revenue to reach approximately $1 million per quarter in Europe by year's end. Additionally, the EMAGIN vascular catheter was submitted for FDA approval, with strategic value anticipated in expanding the robot's applications. Financially, Stereotaxis reported a 39% year-over-year increase in Q4 2024 revenue to $6.3 million and guided for flat system revenue with double-digit overall growth in 2025.Significant Revenue Growth
Fourth quarter revenue increased by 39% year-over-year, from $4.6 million to $6.3 million.
FDA Submissions for Key Innovations
Stereotaxis submitted FDA approvals for MAGIC Sweep and EMAGIN 5F catheters, enhancing their product offerings in EP and vascular procedures.
Strategic Acquisition Impact
The acquisition of APT has expanded catheter development and manufacturing capabilities, contributing positively to recurring revenue.
Product Launches in Europe and US
GenesisX robot received CE Mark in Europe. First firm order for GenesisX in Europe, with expected installation in the summer.
Positive Cash Flow
Stereotaxis reported a positive free cash flow of $1.3 million for the fourth quarter.
---
STXS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
STXS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 03, 2025 | $2.06 | $1.94 | -5.83% |
| Nov 11, 2024 | $1.85 | $2.26 | +22.16% |
| Aug 12, 2024 | $1.80 | $2.01 | +11.67% |
| May 13, 2024 | $2.16 | $2.09 | -3.24% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Stereotaxis (STXS) report earnings?
Stereotaxis (STXS) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is Stereotaxis (STXS) earnings time?
Stereotaxis (STXS) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is STXS EPS forecast?
STXS EPS forecast for the fiscal quarter 2025 (Q1) is -0.05.
---